OsvaRen for hyperphosphataemia in haemodialysis patients

Published: 2010-07-01

Fresenius Medical Care recently demonstrated the effectiveness of its combined phosphate binder OsvaRen (calcium acetate/magnesium carbonate) in the treatment of hyperphosphataemia in haemodialysis patients. The successful CALcium acetate MAGnesium carbonate evaluation (CALMAG) study [1] has shown that OsvaRen reduced serum phosphorus to lower levels than sevelamer hydrochloride and kept serum calcium at comparable levels. The tablets were also well accepted by the patients.

Elevated serum phosphorus levels are an independent predictor of mortality in patients with chronic renal failure and require effective treatment. The head-to-head study found OsvaRen can be a more cost-effective option in the treatment of hyperphosphataemia compared to sevelamer hydrochloride.

OsvaRen has so far been approved in 28 European countries for the treatment of hyperphosphataemia associated with chronic renal insufficiency in patients undergoing dialysis. “The CALMAG study underlines our commitment to the best treatment for dialysis patients”, was the verdict of CEO Dr Emanuele Gatti.

1. http://ndt.oxfordjournals.org/papbyrecent.dtl